Pasar al contenido principal

MORBILIDAD Y MORTALIDAD A LARGO PLAZO TRAS LA ERRADICACION DEL VHC EN PACIENTES COINFECTADOS POR VIH/VHC CON FIBROSIS HEPATICA AVANZADA/CIRROSIS

PI17/00657

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON
Centro realización INSTITUTO DE INVESTIGACION SANITARIA GREGORIO MARAÑON (IiSGM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia
  • González-García, Juan
  • Jiménez-Sousa, María Ángeles
  • Guardiola, Josep M.
  • GESIDA 3603b Cohort Study Group
  • Berenguer, Juan
Sustained virological response (SVR); Anti-HCV therapy; HIV/HCV-coinfected patients, Respuesta virológica sostenida (RVS); Terapia anti-VHC; Pacientes coinfectados por VIH/VHC, Resposta virològica sostinguda (RVS); Teràpia anti-VHC; Pacients infectats amb VIH/VHC, The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR., The HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by the Institute of Health Carlos III, ISCIII, Spanish Health Ministry (Grant nº RD06/0006/0035 and RD12/0017/0037) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF) and Foundation for Research and Prevention of AIDS in Spain (FIPSE). The RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR) and Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado Kith, Óscar|||0000-0001-8372-2604
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Berenguer, Juan|||0000-0001-8541-8200
  • Medrano, Luz María|||0000-0003-3717-5384
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, María Ángeles|||0000-0002-1945-6169
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Navarro, Jordi|||0000-0002-7187-0367
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Fernández-Rodríguez, Amanda|||0000-0002-5110-2213
  • Resino, Salvador|||0000-0001-8783-0450
Objective: To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods: We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results: HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion: HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • de los Santos Gil, Ignacio|||0000-0001-7073-5211
  • Von Wichmann, Miguel Ángel
  • Carrero, Ana
  • Yélamos, María Belén
  • Gómez, Julián
  • Resino, Salvador|||0000-0001-8783-0450
  • Martínez, Isidoro|||0000-0002-9949-9264
  • Miralles, Pilar
  • López, Juan Carlos
  • Parras, Francisco José
  • Padilla Ortega, Belén
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Tejerina, Francisco|||0000-0002-4136-3575
  • Diez, Cristina
  • Pérez Latorre, Leire|||0000-0001-9919-3778
  • Fanciulli, Chiara|||0000-0003-2175-9027
  • Gutiérrez, Isabel
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Carretero, S.
  • Bellón, José-María|||0000-0002-8492-1565
  • Bermejo, Javier|||0000-0002-5241-2758
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Arribas, Jose|||0000-0002-7410-9450
  • Montes, María Luisa|||0000-0003-1748-813X
  • Bernardino, José Ignacio|||0000-0003-3501-8529
  • Pascual Pareja, J. Francisco
  • Zamora, Francisco
  • Peña, Jose M.
  • Arnalich Fernandez, Francisco|||0000-0003-2943-0373
  • Díaz, Marta
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Sanz, Jaime|||0000-0001-6934-4619
  • Bustinduy, M.J.
  • Iribarren, José Antonio
  • Rodríguez-Arrondo, F.
  • Eynde, E.Van den
  • Pérez, M.
  • Ribera, E.
  • Casado, José Luis|||0000-0002-7639-8591
  • Dronda, Fernando|||0000-0002-0443-5816
  • Moreno, A.
  • Pérez Elías, Mª Jesus|||0000-0001-5700-5257
  • Sanfrutos, M.A.
  • Moreno, S.
  • Quereda, Carmen
  • Arranz, A.
  • Casas Díaz, Encarna|||0000-0002-5901-6555
  • Miguel, J.de
  • Schroeder, S.
  • Vergas, J.
  • Téllez, M.J.
  • Vinuesa, D.
  • Muñoz, Lourdes
  • Hernández Quero, José
  • Ferrer, A.
  • Galindo Puerto, María José
  • Ortiz, L.
  • Ortega, Emilio|||0000-0002-2217-8905
  • Montero, M.
  • Blanes, M.
  • Cuellar, S.
  • Lacruz, José
  • Salavert, Miguel|||0000-0002-8571-2124
  • López-Aldeguer, J.
  • Pérez González, Gustavo|||0000-0001-9112-9042
  • Gaspar, G.
  • Yllescas, M.
  • Crespo, P.
  • Aznar, E.
  • Esteban, H.
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)

  • Vázquez-Morón, Sonia|||0000-0002-0977-741X
  • Berenguer, Juan|||0000-0001-8541-8200
  • González García, Juan|||0000-0002-3652-002X
  • Jiménez-Sousa, Ma Ángeles
  • Canorea, Isabel
  • Guardiola Tey, Jose Maria|||0000-0001-5537-2600
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Quereda, Carmen
  • Sanz, José
  • Carrero, Ana
  • Hontañón Antoñana, Víctor|||0000-0003-3070-2647
  • Avellón, Ana|||0000-0003-4425-6350
  • Resino, Salvador|||0000-0001-8783-0450
Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  • Brochado, Óscar
  • Martínez, Isidoro
  • Medrano, Luz
  • González‑García, Juan
  • Jiménez‑Sousa, María Ángeles
  • Navarro Mercadé, Jordi
  • Berenguer, Juan
Coinfecció pel VIH/VHC; Sistema immunitari; Teràpia amb interferó, Coinfección por VIH/VHC; Sistema inmunitario; Terapia con interferón, HIV/HCV coinfection; Immune system; Interferon therapy, Objective To evaluate the impact of hepatitis C virus (HCV) elimination via interferon (IFN)-based therapy on gene expression profiles related to the immune system in HIV/HCV-coinfected patients. Methods We conducted a prospective study in 28 HIV/HCV-coinfected patients receiving IFN-based therapy at baseline (HIV/HCV-b) and week 24 after sustained virological response (HIV/HCV-f). Twenty-seven HIV-monoinfected patients (HIV-mono) were included as a control. RNA-seq analysis was performed on peripheral blood mononuclear cells (PBMCs). Genes with a fold-change (FC) ≥ 1.5 (in either direction) and false discovery rate (FDR) ≤ 0.05 were identified as significantly differentially expressed (SDE). Results HIV/HCV-b showed six SDE genes compared to HIV-mono group, but no significantly enriched pathways were observed. For HIV/HCV-f vs. HIV/HCV-b, we found 58 SDE genes, 34 upregulated and 24 downregulated in the HIV/HCV-f group. Of these, the most overexpressed were CXCL2, PDCD6IP, ATP5B, IGSF9, RAB26, and CSRNP1, and the most downregulated were IFI44 and IFI44L. These 58 SDE genes revealed two significantly enriched pathways (FDR < 0.05), one linked to Epstein-Barr virus infection and another related to p53 signaling. For HIV/HCV-f vs. HIV-mono group, we found 44 SDE genes that revealed 31 enriched pathways (FDR < 0.05) related to inflammation, cancer/cell cycle alteration, viral and bacterial infection, and comorbidities associated with HIV/HCV-coinfection. Five genes were overrepresented in most pathways (JUN, NFKBIA, PIK3R2, CDC42, and STAT3). Conclusion HIV/HCV-coinfected patients who eradicated hepatitis C with IFN-based therapy showed profound gene expression changes after achieving sustained virological response. The altered pathways were related to inflammation and liver-related complications, such as non-alcoholic fatty liver disease and hepatocellular carcinoma, underscoring the need for active surveillance for these patients., This study was supported by grants from Instituto de Salud Carlos III (ISCII; Grant Numbers PI20/00474 and PI17/00657 to JB, PI20/00507 and PI17/00903 to JGG, PI18CIII/00020 to AFR, and PI20CIII/00004 and PI17CIII/00003 to SR). The study was also funded by the RD16CIII/0002/0002 and RD16/0025/0017, and RD16/0025/0018 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Ref. INT16/00100.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

  • Vigón, Lorena
  • Vázquez-Morón, Sonia
  • González-García, Juan
  • Jiménez-Sousa, María Ángeles
  • Guardiola, Josep M.
  • GESIDA 3603b Cohort Study Group
  • Berenguer, Juan
Sustained virological response (SVR); Anti-HCV therapy; HIV/HCV-coinfected patients, Respuesta virológica sostenida (RVS); Terapia anti-VHC; Pacientes coinfectados por VIH/VHC, Resposta virològica sostinguda (RVS); Teràpia anti-VHC; Pacients infectats amb VIH/VHC, The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR., The HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by the Institute of Health Carlos III, ISCIII, Spanish Health Ministry (Grant nº RD06/0006/0035 and RD12/0017/0037) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF) and Foundation for Research and Prevention of AIDS in Spain (FIPSE). The RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR) and Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.